IP Library › Patent Application 17506981
Patent Application
App. No. 17/506,981

FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/506,981
Abstract

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Claims (13)

1 . A compound represented by Formula (VI-6a),

or a pharmaceutically acceptable salt thereof, wherein

X is —CN; and

A is optionally substituted C 1 -C 8 alkyl or optionally substituted heteroaryl.

2 . The compound of claim 1 wherein A is optionally substituted C 1 -C 8 alkyl.

3 . The compound of claim 1 wherein A is optionally substituted heteroaryl.

4 . The compound of claim 1 wherein A is selected from the groups below,

each of which is optionally substituted.

5 . The compound of claim 1 which is represented by Formula (X-e),

or a pharmaceutically acceptable salt thereof, wherein A and X are as defined in claim 1 .

6 . The compound of claim 5 wherein A is selected from the group consisting of

7 . A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

8 . A method of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 1 .